3rd Allogeneic Cell Therapies Summit Europe

A year on from the first European allogenic approval, join 60+ industry experts as they discuss the current landscape and promising emerging pipelines at the 3rd Allogeneic Cell Therapies Summit Europe!

Hear expert insights from Caribou Biosciences, Cellectis, AdaptImmune and many more as they share their recent breakthroughs and strategies to overcome challenges such as alloreactivity, durability, and upscaling their therapies.

As Europe's only conference purely focused on allogeneic research, this is the only opportunity for you to network with other industry leaders, solve shared challenges and have your burning questions answered by leading experts.

Speakers: Anastasios Karadimitris, Co-Director Centre for Haematology, Professor of Haematology Karadimitris Lab, Imperial College London, Augustin de Bettignies, Chief Business Officer, MPC therapeutics, Blake Aftab, Chief Scientific Officer, Adicent Bio, Chris Bravery, Director, Advanced Biologicals, Chris Nowers, Chief Executive Officer, ONK Therapeutics, Dan Crowley, Chief Executive Officer, Remedy Biologics, Emilie Gauthy, Head of Chemistry, Manufacturing and Controls, Zelluna Immunotherapy, Eric Halioua, President and Chief Executive Officer, PDC*line Pharma, Jan Talts, Chief Operating Officer, Amniotics, John Campbell, Chief Scientific Officer, Swarm Oncology, Laurent Poirot, Senior Vice President - Immunology, Cellectis, Mathias Wenes, Chief Technology Officer, MPC therapeutics, Nicolas Theys, Chief Technology Officer, Novadip, Olivier Negre, Chief Scientific Officer, Smart Immune, Roberta Mazza, Scientist, Leucid Bio, Steven Kanner, Chief Scientific Officer, Caribou Biosciences, Tim Allsopp, CTO, Laverock Therapeutics, Xavier Fontana, Principal Scientist - Allogeneic Process Development, AdaptImmune

Others Details

URL:
Brochure: https://go.evvnt.com/2020219-3?pid=6581

Category: Conferences | Science, Health and Medicine | Pharmaceuticals | Clinical